The capability to develop new anti-cancer agents is essential to the mission of the Cancer Center. The Translational Pharmacology and Early Therapeutic Trials (TPETT) Program accomplishes this by: 1) supporting the preclinical development of anti-cancer agents identified by DF/HCC investigators, and 2) defining the toxicity, pharmacokinetics and pharmacodynamics of new agents from the Center, NCI and pharmaceutical companies In Early Phase trials. The overall objective of the TPETT Program is, thus, to foster a coordinated effort: through which promising new leads and agents are developed for evaluation in Early Phase clinical trials and then in Phase 11 in conjunction with the Clinical-based Programs. The Program facilitates the development of anti-cancer agents by combining basic science and clinical resources at the DFCI, MGH, BWH, BIDMC and CHB.
Its Specific Aims are to: 1) strengthen and expand preclinical drug discovery and development efforts;2) perform translational studies to identify responsive subsets of tumors and confirm mechanism of action in the clinic;3) conduct Phase I, l-ll pharmacokinetic/pharmacodynamic trials of new anti-cancer agents with correlative laboratory and imaging studies to define biological endpoints and mechanisms;and 4) develop biomarkers for drug response, resistance and toxicity. The 49 members of this program represent six DF/HCC institutions and eight departments of HMS. In 2009, members received $10.4 million (total costs) in cancer-relevant funding, including $2.7 million from NCI and $370,000 from other peer-reviewed sponsors. In addition, members published 500 papers during the project period (2006 to 2010), of which 12.4% were intra-programmatic, 50% were inter-programmatic, and 25.4% were inter-institutional. The Program has been continuously funded as a CCSG Program for ten years. At the time of the last competitive renewal in 2005, the Program received Excellent merit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601443
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$81,954
Indirect Cost
$60,779
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Yanhui; Comjean, Aram; Roesel, Charles et al. (2016) FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2017 update. Nucleic Acids Res :
Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8
Freedman, Rachel A; Gelman, Rebecca S; Wefel, Jeffrey S et al. (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34:945-52
Mohr, Stephanie E; Hu, Yanhui; Ewen-Campen, Benjamin et al. (2016) CRISPR guide RNA design for research applications. FEBS J 283:3232-8
Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504
Cox, Andrew G; Hwang, Katie L; Brown, Kristin K et al. (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886-96
McKay, Tina B; Hjortdal, Jesper; Sejersen, Henrik et al. (2016) Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment. Sci Rep 6:25534
Nelms, Bradlee D; Waldron, Levi; Barrera, Luis A et al. (2016) CellMapper: rapid and accurate inference of gene expression in difficult-to-isolate cell types. Genome Biol 17:201
Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A et al. (2016) Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell 62:34-46
Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381

Showing the most recent 10 out of 303 publications